Microsaic Regulatory News (MSYS)

11 May 2017

Microsaic Systems plc

("Microsaic", "Microsaic Systems" or the "Company")

Microsaic enhances capabilities of its 4000 MiD® miniaturised mass spectrometer for bioprocessing applications

Microsaic Systems plc (AIM: MSYS), the developer of chip-based mass spectrometry (MS) instruments, has developed a novel technology to enable real-time analysis of proteins in bioprocessing applications, such as in the manufacture of biologic molecules (proteins, antibodies and peptides) for therapeutic and diagnostic uses. The new technology is a tool for rapidly desalting and purifying protein samples prior to their analysis using Microsaic's 4000 MiD® MS instrument. This new technology has the potential to significantly accelerate the industrial purification of biologics.

Glenn Tracey, Microsaic's Chief Operating Officer, commented:

"The benefits of Microsaic's point of use MS technology, in combination with its patented innovation for on-line desalting, allows for the purification of the desired biomolecules in real time. In doing so, analysis times can be reduced from days or even weeks to minutes while offering the potential for significant savings on operational costs. Eight of the top ten selling drugs in 2016 were biologics and the trend for targeted biologic therapeutics is set to continue. Technologies that can accelerate and enhance their production therefore present an opportunity for Microsaic."

Mass spectrometry is a powerful technique which allows the effective implementation of "QbD" (Quality by Design), a key industry and regulatory driver for current and future production of biologics.

About Microsaic Systems

Microsaic Systems plc is a high technology company developing chip-based, bench-top mass spectrometry ("MS") instruments that are designed to improve the efficiency of Pharma R&D. MS is an analytical technique of choice for biochemists across many industry sectors.

Microsaic aims to bring routine MS analysis to the pharmaceutical scientist, providing powerful methods of analysis to enable earlier decision making relating to product identification, purity and bioactivity.

The Company is working with established global companies in preparative and purification science with expertise in Pharma and life sciences to co-develop new, integrated and optimised, application-specific, solutions to improve productivity in the development of small molecule and novel biologic (peptides, antibodies) medicines.

The Microsaic 4000 MiD®, single quadrupole, is the world's smallest MS system, retaining the functionality of larger conventional MS systems, is easier to use by non-specialists, consumes less energy and has lower running costs. The Company is also developing new MS systems, based on its patented chip technologies, to address further areas of emerging need in Pharma R&D.

Microsaic Systems was established in 2001 by a team including founders from Imperial College London, and was admitted to AIM in 2011 (ticker: MSYS).

www.microsaic.com